BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 399.3% from a year ago
Other current liabilities stood at $28.61M at the end of Q1 FY2026, up 399.3% from a year earlier and up 4.4% from the prior quarter.
Context
- Other current liabilities amounted to 6.9% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +399.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.75M USD
- Year-over-year change
- —
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.75M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +399.3% is the 2nd highest of 8, against a peer median of +14.7%.
- Other current liabilities amounts to 6.9% of total assets for BBOT, versus a peer median of 4.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $118.01M USD | — | +146.4% | 38.7% | |
| Mar 2026 | CHF 35.44M CHF | +137.3% | +32449.2% | 14.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $28.61M USD | +399.3% | — | 6.9% |
| Jun 2026 | $27.36M USD | -45.6% | — | 3.8% | |
| Mar 2026 | $26.53M USD | +408.5% | +27.3% | 8.0% | |
SEPNSepterna, Inc. | Sep 2026 | $26.4M USD | -57.2% | +51.2% | 4.3% |
| Aug 2026 | $22.23M USD | +22.8% | +37.3% | 1.9% | |
| Mar 2026 | $13.4M USD | +14.7% | +17.5% | 5.3% | |
| Sep 2026 | $0 USD | — | -22.3% | 0.0% | |
| Sep 2026 | $0 USD | -100.0% | +0.6% | 0.0% | |
| Peer median (excluding BBOT) | — | +14.7% | +32.3% | 4.3% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.